Survivin in cardiovascular diseases and its therapeutic potential

IF 3.5 3区医学 Q2 PHARMACOLOGY & PHARMACY

Vascular pharmacology Pub Date : 2025-02-25 DOI:10.1016/j.vph.2025.107475

Thomas Mousso , Khanh Pham , Rhonda Drewes , Sefunmi Babatunde , Jessica Jong , Alanna Krug , Gabrielle Inserra , John Biber , Joseph A. Brazzo , Sachin Gupte , Yongho Bae

{"title":"Survivin in cardiovascular diseases and its therapeutic potential","authors":"Thomas Mousso , Khanh Pham , Rhonda Drewes , Sefunmi Babatunde , Jessica Jong , Alanna Krug , Gabrielle Inserra , John Biber , Joseph A. Brazzo , Sachin Gupte , Yongho Bae","doi":"10.1016/j.vph.2025.107475","DOIUrl":null,"url":null,"abstract":"<div><div>Aberrant changes in cell behaviors, such as proliferation, apoptosis, and migration, are some of the contributing factors to the development of various cardiovascular diseases (CVDs) and pathologies, including atherosclerosis, neointimal hyperplasia, and heart failure. In recent years, numerous studies have identified survivin, a key player in the anti-apoptotic pathway, to be extensively involved in modulating cellular functioning in cancer, with many reaching clinical trials. Though seemingly different, CVDs and cancer share abundant similarities regarding abnormal cell modifications and behaviors. This overlap has sparked growing interest in investigating survivin as a therapeutic target in the context of CVD. With new findings emerging rapidly, a comprehensive understanding of survivin's role in cardiovascular pathology is crucial to revealing its full therapeutic potential and translating these discoveries into effective treatments. This review discusses recent findings of survivin in CVDs and related pathologies, focusing on its dual role in promoting proliferation and inhibiting apoptosis, specifically in atherosclerosis, neointimal hyperplasia, stroke, hypertension, myocardial infarction, and heart failure. Across different cell types and pathological contexts, survivin plays a pivotal role throughout the disease progression–from the onset of disease development to the facilitation of compensatory mechanisms post-injury–primarily through its function in regulating cell proliferation and apoptosis. Furthermore, given the limited research on survivin as a therapeutic target for CVDs, potential clinical avenues, including YM155 (a survivin inhibitor) or adenoviral, adeno-associated, and lentiviral vectors, are also discussed. Overall, this review highlights survivin as a promising target for mitigating the detrimental effects of CVDs and to provide new perspectives to advance research on the intervention of CVDs and associated pathologies.</div></div>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":"159 ","pages":"Article 107475"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S153718912500014X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aberrant changes in cell behaviors, such as proliferation, apoptosis, and migration, are some of the contributing factors to the development of various cardiovascular diseases (CVDs) and pathologies, including atherosclerosis, neointimal hyperplasia, and heart failure. In recent years, numerous studies have identified survivin, a key player in the anti-apoptotic pathway, to be extensively involved in modulating cellular functioning in cancer, with many reaching clinical trials. Though seemingly different, CVDs and cancer share abundant similarities regarding abnormal cell modifications and behaviors. This overlap has sparked growing interest in investigating survivin as a therapeutic target in the context of CVD. With new findings emerging rapidly, a comprehensive understanding of survivin's role in cardiovascular pathology is crucial to revealing its full therapeutic potential and translating these discoveries into effective treatments. This review discusses recent findings of survivin in CVDs and related pathologies, focusing on its dual role in promoting proliferation and inhibiting apoptosis, specifically in atherosclerosis, neointimal hyperplasia, stroke, hypertension, myocardial infarction, and heart failure. Across different cell types and pathological contexts, survivin plays a pivotal role throughout the disease progression–from the onset of disease development to the facilitation of compensatory mechanisms post-injury–primarily through its function in regulating cell proliferation and apoptosis. Furthermore, given the limited research on survivin as a therapeutic target for CVDs, potential clinical avenues, including YM155 (a survivin inhibitor) or adenoviral, adeno-associated, and lentiviral vectors, are also discussed. Overall, this review highlights survivin as a promising target for mitigating the detrimental effects of CVDs and to provide new perspectives to advance research on the intervention of CVDs and associated pathologies.

Abstract Image

查看原文本刊更多论文

生存素在心血管疾病中的作用及其治疗潜力

细胞行为的异常变化，如增殖、凋亡和迁移，是各种心血管疾病（cvd）和病理（包括动脉粥样硬化、新生内膜增生和心力衰竭）发展的一些促成因素。近年来，大量研究发现，survivin作为抗凋亡通路的关键分子，广泛参与肿瘤细胞功能的调节，许多研究已进入临床试验阶段。心血管疾病和癌症虽然表面上不同，但在细胞异常修饰和行为方面有很多相似之处。这种重叠引起了人们对研究survivin作为心血管疾病治疗靶点的兴趣。随着新发现的迅速出现，全面了解survivin在心血管病理中的作用对于揭示其全部治疗潜力并将这些发现转化为有效的治疗至关重要。本文综述了survivin在心血管疾病及相关病理中的最新发现，重点讨论了survivin在动脉粥样硬化、新生内膜增生、中风、高血压、心肌梗死和心力衰竭中促进细胞增殖和抑制细胞凋亡的双重作用。在不同的细胞类型和病理背景下，survivin主要通过调节细胞增殖和凋亡的功能，在整个疾病进展过程中发挥关键作用，从疾病发生发展到损伤后代偿机制的促进。此外，鉴于survivin作为心血管疾病治疗靶点的研究有限，本文还讨论了潜在的临床途径，包括YM155（一种survivin抑制剂）或腺病毒、腺相关病毒和慢病毒载体。总之，这篇综述强调了survivin作为减轻心血管疾病有害影响的一个有希望的靶点，并为推进心血管疾病和相关病理的干预研究提供了新的视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vascular pharmacology 医学-药学

CiteScore

6.60

自引率

2.50%

发文量

153

审稿时长

31 days

期刊介绍： Vascular Pharmacology publishes papers, which contains results of all aspects of biology and pharmacology of the vascular system. Papers are encouraged in basic, translational and clinical aspects of Vascular Biology and Pharmacology, utilizing approaches ranging from molecular biology to integrative physiology. All papers are in English. The Journal publishes review articles which include vascular aspects of thrombosis, inflammation, cell signalling, atherosclerosis, and lipid metabolism.